[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342902-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342902-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","translational-and-therapeutic-evaluation-of-ras-gtp-inhibition-by-rmc-6236-in-ras-driven-cancers-research-article","Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers - Research article","","RAS-driven cancers comprise up to 30% of human cancers, creating a major unmet therapeutic need. RMC-6236 is an oral, RAS(ON) multi-selective noncovalent inhibitor targeting active, GTP-bound canonical RAS isoforms, including mutant and wild-type variants. It shows potent anticancer activity in RAS-addicted cell lines and induces profound tumor regressions across multiple tumor types in mouse KRASG12X xenograft models. Translational PK/efficacy and PK/PD modeling supported daily 100 mg and 300 mg dosing to achieve tumor control and objective responses. Clinical activity is described in two patients with advanced KRASG12X lung and pancreatic adenocarcinoma at 300 mg daily.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/translational-and-therapeutic-evaluation-of-ras-gtp-inhibition-by-rmc-6236-in-ras-driven-cancers-research-article/342902/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/translational-and-therapeutic-evaluation-of-ras-gtp-inhibition-by-rmc-6236-in-ras-driven-cancers-research-article/342902.png","ImageObject",300,407,{"name":42,"@type":43},"Violet","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does RMC-6236 inhibit in RAS-driven cancers?","Question",{"text":63,"@type":64},"RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor that targets the active, GTP-bound state of canonical RAS isoforms, covering both mutant and wild-type variants.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What preclinical evidence supports the activity of RMC-6236?",{"text":68,"@type":64},"RMC-6236 shows potent anticancer activity across RAS-addicted cell lines, especially those with KRAS codon 12 mutations. In mouse KRASG12X xenograft models, oral dosing was tolerated and produced profound tumor regressions across multiple tumor types.",{"name":70,"@type":61,"acceptedAnswer":71},"How did modeling connect dosing to expected clinical outcomes?",{"text":72,"@type":64},"Translational PK/efficacy and PK/PD modeling predicted that daily doses of 100 mg and 300 mg would achieve tumor control and objective responses, respectively, in patients with RAS-driven tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342902,1790180148,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":99,"preview_page_count":33,"preview_urls":146},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","ReseaRch aRticle  \nTranslational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in  \nRAS-Driven Cancers   \nJingjing Jiang1, Lingyan Jiang1, Benjamin J. Maldonato1, Yingyun Wang1, Matthew Holderfield1, Ida Aronchik1, Ian P. Winters1,2, Zeena Salman1, Cristina Blaj1, Marie Menard1, Jens Brodbeck1, Zhe Chen1, Xing Wei1, Michael J. Rosen2, Yevgeniy Gindin1, Bianca J. Lee1, James W. Evans1, Stephanie Chang1, Zhican Wang1, Kyle J. Seamon1, Dylan Parsons1, James Cregg1, Abby Marquez1, Aidan C.A. Tomlinson1, Jason K. Yano1, John E. Knox1, Elsa Quintana1, Andrew J. Aguirre3,4,5,6, Kathryn C. Arbour7, Abby Reed8, W. Clay Gustafson1, Adrian L. Gill1, Elena S. Koltun1, David Wildes1, Jacqueline A.M. Smith1, Zhengping Wang1, and Mallika Singh1  \nRAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS(ON)  \nmulti-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential for the aforementioned unmet medical need. RMC-6236 exhibited potent anticancer activity across RAS-addicted cell lines, particularly those harboring mutations at codon 12 of KRAS. Notably, oral administration of RMC- 6236 was tolerated in vivo and drove profound tumor regressions across multiple tumor types in a mouse clinical trial with KRASG12X xenograft models. Translational PK/efficacy and PK/PD modeling predicted that daily doses of 100 mg and 300 mg would achieve tumor control and objective responses, respectively, in patients with RAS-driven tumors. Consistent with this, we describe here objective responses in two patients (at 300 mg daily) with advanced KRASG12X lung and pancreatic adenocarcinoma, respectively, demonstrating the initial activity of RMC-6236 in an ongoing phase I/Ib clinical trial (NCT05379985).  \nSIGnIfICAnCE: The discovery of RMC-6236 enables the first-ever therapeutic evaluation of targeted and concurrent inhibition of canonical mutant and wild-type RAS-GTP in RAS-driven cancers. We demonstrate that broad-spectrum RAS-GTP inhibition is tolerable at exposures that induce profound tumor regressions in preclinical models of, and in patients with, such tumors.  \niNtRODUctiON  \nOncogenic mutations in RAS (KRAS, HRAS, and NRAS) proto-oncogenes drive up to 30% of human cancers, accounting for more than 200,000 new cancer cases in the United States each year, most notably of non–small cell lung cancer (NSCLC), colorectal cancer, and pancreatic ductal adenocarcinoma (PDAC; refs. 1, 2) . Most oncogenic RAS mutations are gain-of-function missense alterations at hotspot codons 12, 13, or 61 that result in an impairment of GTP hydrolysis and/ or acceleration of GDP-to-GTP nucleotide exchange by these small GTPases, such that the normally tightly regulated cellular equilibrium of a RAS protein shifts predominantly toward the active, GTP-bound (RAS(ON)) state. This shift drives increased oncogenic flux via activation of downstream effectors and signaling pathways linked to cell proliferation and survival (3) . Until the recent development of direct inhibitors ofKRASG12C, RAS was largely considered undruggable (4) .  \nKRAS is most frequently mutated in PDAC (92% of patients), followed by colorectal cancer (49%) and NSCLC (29%; refs. 1, 2), predominantly at codon 12 in these three  \n1Revolution Medicines, Inc., Redwood City, California. 2D2G Oncology, Inc., Mountain View, California. 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 4Harvard Medical School, Boston, Massachusetts. 5Broad Institute of MIT and Harvard, Cambridge, Massachusetts. 6Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 7Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 8The Christ Hospital Cancer Center, Cincinnati, Ohio.  \nCorrected online September 5, 2025.  \nL. Jiang and B.J. Maldonato contributed equally to this article.  \nCorresponding Authors: Mallika Singh, ","cbCaiaBFYStaixjP","https://ap.wps.com/l/cbCaiaBFYStaixjP","pdf",30381317,24,"English","# Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236\n## Abstract and significance\n## Introduction and oncogenic RAS biology","[{\"question\":\"What does RMC-6236 inhibit in RAS-driven cancers?\",\"answer\":\"RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor that targets the active, GTP-bound state of canonical RAS isoforms, covering both mutant and wild-type variants.\"},{\"question\":\"What preclinical evidence supports the activity of RMC-6236?\",\"answer\":\"RMC-6236 shows potent anticancer activity across RAS-addicted cell lines, especially those with KRAS codon 12 mutations. In mouse KRASG12X xenograft models, oral dosing was tolerated and produced profound tumor regressions across multiple tumor types.\"},{\"question\":\"How did modeling connect dosing to expected clinical outcomes?\",\"answer\":\"Translational PK/efficacy and PK/PD modeling predicted that daily doses of 100 mg and 300 mg would achieve tumor control and objective responses, respectively, in patients with RAS-driven tumors.\"}]","Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers - Research article | PDF",1790048734,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92d46dafd71ef9458ba977215b652029.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57504afe420167ede73ba4d7a1bd3532.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d61be1ea28b68ec66d3cea8f4c3eda1b.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c922a408af7522ec728878b3690f8d1c.webp",980,1311]